A novel anti-influenza combined therapy assessed by single cell RNA-sequencing

To develop a novel treatment against influenza, we combined virucidal sialylated cyclodextrins with interferon lambda and demonstrated, in human airway epithelia, that the two compounds inhibit the replication of a clinical H1N1 strain more efficiently when administered together rather than alone. We investigated the mechanism of action of the combined treatment by single cell RNA sequencing analysis and found that both the single and combined treatments impair viral replication to different extents across distinct epithelial cell types. We also showed that each cell type comprises multiple sub-types, whose proportions are altered by H1N1 infection, and assess the ability of the treatments to restore them. Reconstituted human airway epithelia infected with Influenza A and treated with cyclodextrins, interferon lambda or both. UPDATE: [Mar-22-2024] The Sample titles and characteristics were corrected. The associations of the raw data and processed data files with the Samples (GSMxxx) did not change.